Show items per page
Elements: 5
Page 1 on 1
 TitleAuthors / EditorsDate
add to browser selection
Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Finckh, Axel; Ciurea, A.; Brulhart, L.; Moller, B.; ... Gabay, Cem 2010
add to browser selection
Comparative effectiveness of rheumatoid arthritis therapies Finckh, Axel 2010
add to browser selection
Influence of anti-infliximab antibodies and residual infliximab concentrations on the occurrence of acquired drug resistance to infliximab in rheumatoid arthritis patients Finckh, Axel; Dudler, Jean; Wermelinger, Felix; Ciurea, Adrian; ... Bas, Sylvette 2010
add to browser selection
Cost-effectiveness of biologics in early rheumatoid arthritis Finckh, Axel; Bansback, Nick; Liang, Matthew H. 2010
add to browser selection
Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis Du Pan, Sophie Martin; Dehler, Silvia; Ciurea, Adrian; Ziswiler, Hans-Rudolf; ... Finckh, Axel 2009